Last edition
News about "Phase 2 clinical trial ASC30"
Ascletis Pharma Completes US Phase 2 Enrollment for ASC30 GLP-1R Agonist
Ascletis Pharma completes US Phase 2 enrollment for ASC30, an oral GLP-1R agonist for diabetes. The 13-week study evaluates safety, efficacy, and tolerability in 100 patients, with topline results expected in Q3 2026.
Phase 2 Clinical Trial ASC30 | 27/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members